Recent studies have demonstrated that in patients with BRAFV600E-positive ATC, neoadjuvant therapy with dual BRAF/MEK inhibition using dabrafenib and trametinib can convert an initially unresectable tumor into a resectable state, thereby prolonging progression-free survival (PFS) and OS (14, 15). The gene discussed is MAP2K7; the disease is neoplasm.